Market Place
Sourcing Support
Ulipristal acetate for uterine fibroids: EMA recommends restricting use
13 Nov 2020 //
EMA
AbbVie withdraws uterine fibroids drug from Canada
01 Oct 2020 //
REUTERS
AbbVie withdraws uterine fibroids drug from Canada
30 Sep 2020 //
REUTERS
Health Canada Issues Recall of Allergan Canada`s Fibristal 5MG
24 Sep 2020 //
HEALTH CANADA
Health Canada reviews safety of drug Fibristal following new liver injury
16 Sep 2020 //
HEALTHYCANADA
EMA safety recommends withdrawal of ulipristal acetate marketing authorisation
10 Sep 2020 //
EU PHARMACEUTICALREVIEW
EMA’s PRA recommends revoking marketing authorisation of ulipristal acetate
06 Sep 2020 //
PHARMABIZ
EMA recommends pulling ulipristal acetate for fibroids
04 Sep 2020 //
RAPS
Allergan, following years of turmoil and resistance, heads for split
19 Jun 2019 //
FIERCE PHARMA
Myovant hits goal in uterine fibroid phase 3
15 May 2019 //
FIERCE BIOTECH
Hedge funder renews call for Allergan CEO-chairman split
06 Feb 2019 //
FIERCE PHARMA
Health Canada places restrictions on Allergan`s fibroid treatment Esmya
11 Jan 2019 //
REUTERS
Health Canada safety review finds link between Fibristal and risk of liver injury
11 Jan 2019 //
HEALTH CANADA
AbbVie`s Orilissa makes its uterine fibroids case with double phase 3 win
16 Nov 2018 //
FIERCE PHARMA
AbbVie preps uterine fibroid filing after phase 3 win
15 Nov 2018 //
PM LIVE
Gedeon Richter`s Ulipristal Acetate Receives Marketing Approval in Europe
06 Sep 2018 //
EMA
US FDA seeks additional information from Allergan`s ulipristal acetate NDA
23 Aug 2018 //
PHARMABIZ
FDA rejects Allergan’s fibroids drug, citing liver safety concerns
23 Aug 2018 //
PHARMAPHORUM
AbbVie posts more promising late-stage data for elagolix
22 Aug 2018 //
ENDPTS
FDA rejects Allergan`s Esmya fibroid treatment
22 Aug 2018 //
REUTERS
FDA turns thumbs down on Allergan’s optimistic case for uterine fibroid drug
22 Aug 2018 //
ENDPTS
Allergan`s Esmya rejection deals a blow to women`s health sale prospects
22 Aug 2018 //
FIERCE PHARMA
Esmya: new measures to minimise risk of rare but serious liver injury
10 Aug 2018 //
EMA
Gedeon Richter Plc`s Generic Ulipristal Acetate Receives Approval in Europe
04 Jul 2018 //
EMA
CAR-T therapies leap towards EU approval
02 Jul 2018 //
PHARMATIMES
Allergan might just have an activist fight on its hands
18 May 2018 //
FIERCE PHARMA
Health Canada to conduct review of safety,Fibristal (ulipristal acetate)
15 Mar 2018 //
NEWSWIRE
FDA pushes back PDUFA date on Allergan’s uterine fibroid drug
01 Mar 2018 //
FIERCE BIOTECH
MHRA suspends new prescriptions of fibroid drug Esmya
21 Feb 2018 //
PMLIVE
New prescriptions of Allergan’s Esyma on hold
21 Feb 2018 //
PHARMA TIMES
EMA nixes new Esmya patients as liver-safety probe continues
12 Feb 2018 //
FIERCE PHARMA
Allergan Presented New Ph3 Data of Ulipristal Acetate in Women Uterine Fibroids
31 Oct 2017 //
PR NEWSWIRE
CDC backs GSK’s Shingrix over Merck & Co’s Zostavax
27 Oct 2017 //
PMLIVE
Teva Pharms USA`s Generic Logilia Receives Approval In US
13 Feb 2017 //
FDA
Allergan plans to file oral uterine fibroid drug in US by year-end
17 Jan 2017 //
PMLIVE
Allergan, Gedeon report positive results from phIII trial of ulipristal acetate
17 Jan 2017 //
PHARMABIZ
Allergan, Richter Announce Positive PhIII Result for Ulipristal Acetate 5/10 mg
10 May 2016 //
PR NEWSWIRE
SMC allows wider use of Gedeon Richter`s Esmya
23 Mar 2016 //
PHARMATIMES
Golin Health wins HRA Pharma and Atlantis Healthcare accounts
29 Jan 2016 //
PM LIVE
Allergan`s depression drug bags a `breakthrough` tag on the way to Phase III
29 Jan 2016 //
FIERCE BIOTECH
Results of PEARL IV Study Presented at EU Society of Gynaecological Endoscopy
09 Oct 2015 //
PR NEWSWIRE
